GU Cancers 2022 | Novel immune therapeutics for adjuvant treatment of kidney cancer

Hyung Kim, MD, Cedars-Sinai Medical Center, Los Angeles, CA, talks about a new trial investigating a drug targeting HIF-2α, in combination with pembrolizumab, as an adjuvant therapy for patients with kidney cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.